Viatris has the Profitability Rank of 6.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Viatris's Operating Margin % for the quarter that ended in Dec. 2023 was -5.53%. As of today, Viatris's Piotroski F-Score is 8.
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Profitability Rank Distribution
For the Drug Manufacturers industry and Healthcare sector, Viatris's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Viatris's Profitability Rank falls into.
Viatris Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Viatris has the Profitability Rank of 6.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Viatris's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Viatris has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Viatris (Viatris) Business Description
Traded in Other Exchanges
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
| Andrew Cuneo |
officer: See Remarks |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Xiangyang (sean) Ni |
officer: President, Greater China |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Leo Frans Groothuis |
director |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Scott Andrew Smith |
director |
C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Elisha W Finney |
director |
C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304 |
| Van Der Meer Mohr Pauline |
director |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Menassie Taddese |
officer: See Remarks |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Robert J Coury |
director, officer: Executive Chairman |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| W Don Cornwell |
director |
|
| Brian Roman |
officer: Global General Counsel |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Anthony Mauro |
officer: See Remarks |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| James M Kilts |
director |
120 PARK AVE, NEW YORK NY 10017 |
| Melina E Higgins |
director |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| Ian C Read |
director |
PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Dillon Joellen Lyons |
director |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL |
Viatris (Viatris) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your